Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. - Wikidata - awgldk - TriplyDB

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.

http://www.wikidata.org/entity/Q33610029

about

Biomarkers in dementia: clinical utility and new directions Amidated and Ibuprofen-Conjugated Kyotorphins Promote Neuronal Rescue and Memory Recovery in Cerebral Hypoperfusion Dementia Model An update on semantic dementia: genetics, imaging, and pathology Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.CSF neurofilament light chain reflects corticospinal tract degeneration in ALS.The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer's disease.Plasma neurofilament light chain predicts progression in progressive supranuclear palsy Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes.Neurofilament light chain: a biomarker for genetic frontotemporal dementia Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.Key emerging issues in frontotemporal dementia.Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.Imaging and fluid biomarkers in frontotemporal dementia.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders.Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.Neurofilaments and Neurofilament Proteins in Health and Disease.Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.New routes in frontotemporal dementia drug discovery.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.Precipitous Deterioration of Motor Function, Cognition, and Behavior.Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.

P2860

Q27007086-25CD717E-23FD-4884-8400-AF9D75CA4675 Q27323343-0E585455-646A-4493-822F-59E0E693112E Q28069807-E0BE68C1-62B5-4D74-9E02-067FFC4FD1D3 Q34031302-5D9F5A98-4A6D-4779-9B7D-A407A6447578 Q34633220-765DC701-1700-481C-AAB8-F7F4BAF3537C Q35093695-AA18533C-CD2D-431C-877B-FE303A71DFEF Q35204586-55A92273-6EC7-4F66-9A4F-F5AD094ADD4F Q35735066-74895D37-E2BE-42A4-AF15-B20086785584 Q35935100-41FBB566-8346-4B12-9CDD-80980E25F60E Q36073680-62428936-302E-44B4-9278-E9F60AB1DF7F Q36639639-1782F12F-3959-4D9F-9F69-694C0D19B1DD Q36933708-F3823AE7-13DA-428C-B95A-BD7BC6C1BF65 Q37208495-E07D5825-44DD-4D55-85F7-531E1A46804B Q37304614-7F0D50A3-21F0-4979-9DA1-7F0D08751836 Q37307467-802179CD-80BD-48A1-835B-CF0A46D93EAE Q37407370-150AA0CC-1AFB-48FA-8ECC-5FCB790BDF1D Q37494873-F5471087-8CB9-47F0-9C67-B9C95512068C Q37566888-D09FEA0F-45AB-489C-AB5A-59B8A57B64EE Q37676938-AB9C0144-195D-4B0D-ACE7-154081735DDC Q37703133-93FB1E30-D618-40E5-98BC-6BA00BF742BD Q38392505-B36F77EA-3AF2-40D0-8962-6CB1CB8EF46B Q38580586-C31FE1AC-B755-45D9-8AE3-AD550331D994 Q38666247-822596CE-29D5-439B-8C7D-27CF6F2AEC49 Q38670219-33E26DF3-D6C8-4FF8-BFA8-80708B58DA48 Q38825497-469B802A-EE04-4CCC-943D-763C423CA94B Q38949756-E3BB0AF1-7B4F-4DCF-AEA2-7BD3F3AEB4C0 Q38980003-B02E87DF-853B-49D3-940A-EC3A286AB6D8 Q39217671-B8EDA508-B685-4B68-AA3F-9D1A8B180B62 Q39339614-A574CF43-09E1-4B9D-BA13-350168A8EC57 Q39342351-842AD0CA-DAF6-4036-BADF-7D2BB7335241 Q39344391-4B2F697D-139D-4EF9-B4C6-B5E9DB84D596 Q39366291-C88B0CD7-C408-4A78-8605-ACBEB8537FCC Q40262441-7AF86DE1-3DE0-4CB1-9B12-EBBF3E267D4B Q40777128-AB7D47C2-9802-4E6E-804F-89A849553CCB Q42287644-ECBD9361-8627-4094-9974-319B0B0FE1AE Q42656279-DD69757D-51EB-4183-AD36-03876A313823 Q46072409-7CDD9D98-5C7E-46D6-843C-71D2569D4B43 Q46427093-E5C0AABD-4436-407E-B1E7-63E8E97B7E9B Q47165587-5EAC36B1-D7FE-49F9-9D68-1C1504FB0D4F Q47315423-74CB99B7-1D15-4380-9CAA-9C7ED0552E15

P2860

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.

http://www.wikidata.org/entity/Q33610029

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@ast

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@en

type

label

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@ast

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@en

prefLabel

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@ast

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@en

P1433

Q33610029-A9E90D7A-1AE8-41BC-B822-4CDB3070F187

P1476

Q33610029-A27BE4BD-E1FC-4F42-8C03-937CC273C38D

P2093

Q33610029-0E13A462-76BC-4478-BEA5-6BDE9EA77328

Q33610029-0ED986A7-89E8-436F-A3F2-3990CBA5EE6D

Q33610029-1CA4200E-980D-47A1-8EC3-72C4012AA192

Q33610029-702587A1-1CA7-4B23-A89C-C380DA5C62D1

Q33610029-7A4C0FB7-6650-43B1-8C5C-33A6C8869B0B

Q33610029-94838A1C-F51A-49DD-91E7-7E35035492B8

Q33610029-955E5B9A-60FC-4DBD-9E23-89A886763947

Q33610029-9B53AB60-CA3D-4169-A436-18DFDFB81B9A

Q33610029-B06C536E-6498-4B61-8E18-65E21D167C29

Q33610029-E7FD1E0D-D33A-4F26-9352-4C00E3186A98

P2860

Q33610029-18917728-8A5C-4E92-B2E0-41DC80E125EB

Q33610029-18EAA374-742E-4314-B698-A2291E2499B8

Q33610029-1D98C9D1-F54E-40D3-8711-13A49B8D5D60

Q33610029-25E4AF26-0F6B-4FD9-AA1E-7A83D747867C

Q33610029-2E889A83-79D4-4CD3-B748-5D0DA5411A20

Q33610029-2E963E24-DCBB-4AC7-8AC5-33820D40227B

Q33610029-34A81224-F32B-4B31-99CC-EBEC74030B7F

Q33610029-3D9AC8A5-294A-4555-B2F9-288F3517D24F

Q33610029-3F30F690-F5CA-4F34-9E5E-04E26A48E76E

Q33610029-400E3652-F9DA-40B6-8C09-63A40F5A4F30

P304

Q33610029-6352FBDA-F75A-4834-9E0B-E28E21D3E84C

P31

Q33610029-A59DE2AA-585F-4430-B955-9F84322D5778

P356

Q33610029-E8AA83F8-871D-442D-862A-FB8717AAF804

P433

Q33610029-A2B1A2A1-8233-4190-BEC8-B250AA4B693D

P478

Q33610029-B21E3EAC-E03A-48E2-A136-B611E1C95544

P50

Q33610029-05AB2FB2-417A-4D74-8B59-3C9A473C4FF2

Q33610029-06A36CEA-129E-4998-A567-9307E8023825

Q33610029-43B87CF3-DB95-4AA5-BCE7-418F08BC6319

Q33610029-4EB6950A-B682-41A9-8F90-2F34D9552A12

P577

Q33610029-D24FD3A6-C61E-42B3-A2E8-3EEE6BCAC783

P5875

Q33610029-442BBA93-29A3-452A-9664-EF377BF2023B

P698

Q33610029-B8F797EA-9FF7-49EE-B391-88FBBADA0745

P921

Q33610029-846AC7A3-0BBA-4273-BD04-04BE102E182A

P932

Q33610029-0806AB9D-4F82-456E-84AC-41BA6B17BEFA

P356

P1433

Annals of Neurology

P1476

Cerebrospinal fluid neurofilam ...... n frontotemporal degeneration.

@en

P2093

Anna Karydas

http://www.w3.org/2001/XMLSchema#string

Carole S Scherling

http://www.w3.org/2001/XMLSchema#string

Flora Berisha

http://www.w3.org/2001/XMLSchema#string

Giovanni Coppola

http://www.w3.org/2001/XMLSchema#string

Howard Rosen

http://www.w3.org/2001/XMLSchema#string

Jere Meredith

http://www.w3.org/2001/XMLSchema#string

Joel H Kramer

http://www.w3.org/2001/XMLSchema#string

Kristen Klepac

http://www.w3.org/2001/XMLSchema#string

Lea T Grinberg

http://www.w3.org/2001/XMLSchema#string

Michael Ahlijanian

http://www.w3.org/2001/XMLSchema#string

P2860

Classification of primary progressive aphasia and its variants

Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Clinicopathological correlations in corticobasal degeneration

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

P304

116-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.24052

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Bruce L. Miller

Gil D Rabinovici

P577

2014-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258637802

http://www.w3.org/2001/XMLSchema#string

P698

24242746

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

4020786

http://www.w3.org/2001/XMLSchema#string